{"content":"<li class=\"n-box-item date-title\" data-end=\"1391576399\" data-start=\"1391490000\" data-txt=\"Saturday, December 21, 2019\">Tuesday, February  4, 2014</li><li class=\"n-box-item sa-box-item\" data-id=\"1548501\" data-ts=\"1391558041\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MMM\" target=\"_blank\">MMM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1548501-3m-announces-12b-buyback-shares-plus-2_6-percent-ah\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">3M announces $12B buyback, shares +2.6% AH</a></h4><ul>\n<li>3M (NYSE:<a href=\"https://seekingalpha.com/symbol/MMM\" title=\"3M Company\">MMM</a>) is launching a new $12B buyback program. The program replaces 3M's existing authorization, and is good for repurchasing 14% of outstanding shares at current levels.</li>\n<li>3M spent $5.2B on buybacks in 2013, and $1.7B just in Q4. Will new debt be issued to pay for additional repurchases? 3M ended Q4 with $4.9B in cash/investments, and $6B in debt.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1548501\" data-linked=\"3M announces $12B buyback, shares +2.6% AH\" data-tweet=\"$MMM - 3M announces $12B buyback, shares +2.6% AH https://seekingalpha.com/news/1548501-3m-announces-12b-buyback-shares-plus-2_6-percent-ah?source=tweet\" data-url=\"https://seekingalpha.com/news/1548501-3m-announces-12b-buyback-shares-plus-2_6-percent-ah\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:54 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1548331\" data-ts=\"1391553578\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1548331-after-hour-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hour Gainers / Losers</a></h4><ul><li><b>Top gainers, as of 5:15 p.m.:</b> <a href='https://seekingalpha.com/symbol/MYGN' title='Myriad Genetics, Inc.'>MYGN</a> <font color='green'>+15.5%</font>. <a href='https://seekingalpha.com/symbol/USNA' title='USANA Health Sciences Inc.'>USNA</a> <font color='green'>+14.0%</font>. <a href='https://seekingalpha.com/symbol/OCLR' title='Oclaro, Inc.'>OCLR</a> <font color='green'>+8.4%</font>. <a href='https://seekingalpha.com/symbol/IDIX' title='Idenix Pharmaceuticals, Inc.'>IDIX</a> <font color='green'>+7.3%</font>. <a href='https://seekingalpha.com/symbol/GIMO' title='Gigamon, Inc.'>GIMO</a> <font color='green'>+4.9%</font>.</li><li><b>Top losers, as of 5:15 p.m.:</b> <a href='https://seekingalpha.com/symbol/QNST' title='QuinStreet, Inc.'>QNST</a> <font color='red'>-15.1%</font>. <a href='https://seekingalpha.com/symbol/XOOM' title='Xoom, Inc.'>XOOM</a> <font color='red'>-9.4%</font>. <a href='https://seekingalpha.com/symbol/HAIN' title='The Hain Celestial Group, Inc.'>HAIN</a> <font color='red'>-7.9%</font>. <a href='https://seekingalpha.com/symbol/KEYW' title='KEYW Holding'>KEYW</a> <font color='red'>-6.9%</font>. <a href='https://seekingalpha.com/symbol/CHRW' title='C.H. Robinson Worldwide Inc.'>CHRW</a> <font color='red'>-6.5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"1548331\" data-linked=\"After Hour Gainers / Losers\" data-tweet=\"$MYGN $USNA $OCLR - After Hour Gainers / Losers https://seekingalpha.com/news/1548331-after-hour-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/1548331-after-hour-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:39 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1548231\" data-ts=\"1391552613\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GNW\" target=\"_blank\">GNW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1548231-business-is-good-at-genworth\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Business is good at Genworth</a></h4><ul>\n<li>Book value per share excluding AOCI of $24.03 is up from $22.95 at the end of 2012.</li>\n<li>U.S. life insurance net operating income of $119M up from $73M a year ago. Global mortgage insurance NOI of $107M slips from $133M a year ago (the year-ago figure, though, included a $78M tax benefit from Canada).</li>\n<li>Company has received approvals from 41 states for boosting LTC in force premiums with the goal of $250M-$300M in additional premiums by 2017.</li>\n<li>Dividends paid to the holding company by international mortgage insurance of $67M during Q, bringing the full year amount to $240M.</li>\n<li>\n<a href=\"http://investor.genworth.com/\" target=\"_blank\">CC</a> tomorrow at 8:30 ET</li>\n<li>\n<a href=\"https://seekingalpha.com/symbol/GNW\" title=\"Genworth Financial, Inc.\">GNW</a> <font color=\"green\">+4.6%</font> AH</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1548231\" data-linked=\"Business is good at Genworth\" data-tweet=\"$GNW - Business is good at Genworth https://seekingalpha.com/news/1548231-business-is-good-at-genworth?source=tweet\" data-url=\"https://seekingalpha.com/news/1548231-business-is-good-at-genworth\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:23 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1548201\" data-ts=\"1391552342\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XOOM\" target=\"_blank\">XOOM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1548201-xoom-minus-14_6-percent-ah-on-soft-guidance-15m-acquisition-announced\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Xoom -14.6% AH on soft guidance; $15M acquisition announced</a></h4><ul>\n<li>Though <a href=\"https://seekingalpha.com/symbol/XOOM\" title=\"Xoom, Inc.\">XOOM</a> beat Q4 estimates, the company expects Q1 revenue of $33M-$34M and EPS of -$0.08 to -$0.05, below a consensus of $34.2M and $0.07. In addition, while full-year revenue guidance ($155M-$160M) is above a $152.7M consensus, EPS guidance ($0.03-$0.10) is well below a $0.37 consensus.</li>\n<li>In tandem with its Q4 report, Xoom announces it has acquired BlueKite, developer of a cross-border payments platform that <a href=\"http://techcrunch.com/2013/01/09/bluekite-raises-1-5-million-to-help-u-s-immigrants-pay-bills-abroad/\" target=\"_blank\">allows U.S. users</a> to pay bills for families abroad, for $15M in cash and stock. BlueKite has 30 employees split between the U.S. and Guatemala, and partnerships with dozens of Florida retail stores.</li>\n<li>Xoom's opex rose 31% Y/Y in Q4 (compares with rev. growth of 53%). Gross sending volume +45% to $1.4B, transactions +42% to 2.74M, active customers +36% to 1.06M, and new customers +10% to 113K.</li>\n<li>\n<a href=\"https://seekingalpha.com/news/1547891-xoom-inc-beats-by-0_07-beats-on-revenue\" target=\"_blank\">Q4 results</a>, PR</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1548201\" data-linked=\"Xoom -14.6% AH on soft guidance; $15M acquisition announced\" data-tweet=\"$XOOM - Xoom -14.6% AH on soft guidance; $15M acquisition announced https://seekingalpha.com/news/1548201-xoom-minus-14_6-percent-ah-on-soft-guidance-15m-acquisition-announced?source=tweet\" data-url=\"https://seekingalpha.com/news/1548201-xoom-minus-14_6-percent-ah-on-soft-guidance-15m-acquisition-announced\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:19 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1548161\" data-ts=\"1391551819\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IDIX\" target=\"_blank\">IDIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1548161-idenix-plus-7-percent-as-klarman-boosts-stake-and-involvement\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Idenix +7% as Klarman boosts stake and involvement</a></h4><ul><li>Baupost's <a href=\"http://www.sec.gov/Archives/edgar/data/1061768/000106176814000008/idix13damend1.htm\" target=\"_blank\">latest 13D</a> shows a 39.8%, or 53.3M share stake in Indenix Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/IDIX' title='Idenix Pharmaceuticals, Inc.'>IDIX</a>) vs 35% at <a href=\"https://seekingalpha.com/news/1529801-idenix-raises-over-100m-from-baupost\" target=\"_blank\">last report</a>. Baupost also say's it's engaged management and has been granted observer rights to board meetings.</li><li>Shares&nbsp;<font color='green'>+7.3%</font>&nbsp;AH</li></ul><div class=\"tiny-share-widget\" data-id=\"1548161\" data-linked=\"Idenix +7% as Klarman boosts stake and involvement\" data-tweet=\"$IDIX - Idenix +7% as Klarman boosts stake and involvement https://seekingalpha.com/news/1548161-idenix-plus-7-percent-as-klarman-boosts-stake-and-involvement?source=tweet\" data-url=\"https://seekingalpha.com/news/1548161-idenix-plus-7-percent-as-klarman-boosts-stake-and-involvement\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:10 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1548151\" data-ts=\"1391551613\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GNW\" target=\"_blank\">GNW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1548151-genworth-financial-inc-beats-by-0_08-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Genworth Financial, Inc. beats by $0.08, beats on revenue</a></h4><ul>\n<li>Genworth Financial, Inc. (NYSE:<a href=\"https://seekingalpha.com/symbol/GNW\" title=\"Genworth Financial, Inc.\">GNW</a>): Q4 EPS of $0.38 <font color=\"green\">beats by $0.08</font>.</li>\n<li>Revenue of $2.41B (-4.4% Y/Y) <font color=\"green\">beats by $30M</font>.</li>\n<li>Shares <font color=\"green\">+1.5%</font> AH.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1548151\" data-linked=\"Genworth Financial, Inc. beats by $0.08, beats on revenue\" data-tweet=\"$GNW - Genworth Financial, Inc. beats by $0.08, beats on revenue https://seekingalpha.com/news/1548151-genworth-financial-inc-beats-by-0_08-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/1548151-genworth-financial-inc-beats-by-0_08-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1548131\" data-ts=\"1391551427\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MYGN\" target=\"_blank\">MYGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1548131-myriad-flies-after-beat-raise-and-acquisition\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Myriad flies after beat, raise, and acquisition</a></h4><ul>\n<li>Molecular diagnostic testing revenue of $196.2M in FQ2 up 39% from a year ago. \"We believe that our increased sales, marketing, and education efforts resulted in wider acceptance of our molecular diagnostic tests by the medical community and increased patient testing volumes.\"</li>\n<li>Oncology revenue of $101.6M up 12%. Women's health revenue of $94.6M up 90%.</li>\n<li>Net income of $50.4M up 44% from a year ago.</li>\n<li>3.2M shares repurchased for $77.8M. FQ2 weighted average share count of 76.8M compares to 84.2M a year ago.</li>\n<li>FY2014 EPS outlook is boosted to $2.09-$2.12 from $1.92-$1.97 on revenue of $740M-$750M from $700M-$715M.</li>\n<li>\n<a href=\"https://seekingalpha.com/news/1547551-myriad-genetics-to-buy-crescendo-bioscience\" target=\"_blank\">Earlier</a>: Buying Crescendo Bioscience for $270M.</li>\n<li>\n<a href=\"https://seekingalpha.com/symbol/MYGN\" title=\"Myriad Genetics, Inc.\">MYGN</a> <font color=\"green\">+15.5%</font> AH</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1548131\" data-linked=\"Myriad flies after beat, raise, and acquisition\" data-tweet=\"$MYGN - Myriad flies after beat, raise, and acquisition https://seekingalpha.com/news/1548131-myriad-flies-after-beat-raise-and-acquisition?source=tweet\" data-url=\"https://seekingalpha.com/news/1548131-myriad-flies-after-beat-raise-and-acquisition\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1548081\" data-ts=\"1391550834\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VOCS\" target=\"_blank\">VOCS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1548081-vocus-inc-beats-by-0_04-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vocus, Inc. beats by $0.04, beats on revenue</a></h4><ul><li>Vocus, Inc. (NASDAQ:<a href='https://seekingalpha.com/symbol/VOCS' title='Vocus, Inc.'>VOCS</a>): Q4 EPS of $0.07 <font color='green'>beats by $0.04</font>.</li><li>Revenue of $47.5M (+0.2% Y/Y) <font color='green'>beats by $2.24M</font>.</li><li>Shares <font color='green'>+1.5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"1548081\" data-linked=\"Vocus, Inc. beats by $0.04, beats on revenue\" data-tweet=\"$VOCS - Vocus, Inc. beats by $0.04, beats on revenue https://seekingalpha.com/news/1548081-vocus-inc-beats-by-0_04-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/1548081-vocus-inc-beats-by-0_04-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:53 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1548071\" data-ts=\"1391550825\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OCLR\" target=\"_blank\">OCLR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1548071-oclaro-plus-10_4-percent-ah-on-revenue-margin-beat-in-line-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oclaro +10.4% AH on revenue/margin beat, in-line guidance</a></h4><ul>\n<li>Though Oclaro (NASDAQ:<a href=\"https://seekingalpha.com/symbol/OCLR\" title=\"Oclaro, Inc.\">OCLR</a>) slightly missed FQ2 EPS estimates (while beating on revenue), the company posted a gross margin of 17%, up from 13% in FQ1 and 15% a year ago, and above guidance of 10%-14%. The <a href=\"https://seekingalpha.com/news/1323482-ii-vi-decides-to-buy-oclaros-amplifier-unit-oclaro-cfo-resigning\" target=\"_blank\">recent sale</a> of two businesses to II-VI may have helped out.</li>\n<li>Oclaro expects FQ3 revenue of $93M-$103M, in-line with a $97.3M consensus. Gross margin for the seasonally weak quarter is expected to be in a range of 13%-17%, and adjusted EBITDA in a range of -$13M to -$9M (compares with -$10.7M in FQ2).</li>\n<li>Last week, rival <a href=\"https://seekingalpha.com/news/1539381-jds-uniphase-issues-solid-guidance-announces-two-acquisitions\" target=\"_blank\">JDS Uniphase</a> provided in-line guidance to the approval of investors on edge over near-term carrier capex trends.</li>\n<li>R&amp;D spend fell 9% Y/Y to $16.4M, and SG&amp;A spend 11% to $18.6M.</li>\n<li>\n<a href=\"http://investor.oclaro.com/eventdetail.cfm?EventID=139919\" target=\"_blank\">CC</a> at 5PM ET. <a href=\"https://seekingalpha.com/news/1547661-oclaro-inc-misses-by-0_02-beats-on-revenue\" target=\"_blank\">FQ2 results</a>, PR.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1548071\" data-linked=\"Oclaro +10.4% AH on revenue/margin beat, in-line guidance\" data-tweet=\"$OCLR - Oclaro +10.4% AH on revenue/margin beat, in-line guidance https://seekingalpha.com/news/1548071-oclaro-plus-10_4-percent-ah-on-revenue-margin-beat-in-line-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/1548071-oclaro-plus-10_4-percent-ah-on-revenue-margin-beat-in-line-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:53 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1547931\" data-ts=\"1391549378\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DATA\" target=\"_blank\">DATA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1547931-tableau-plus-14_2-percent-ah-after-trouncing-estimates-on-93-percent-license-growth\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tableau +14.2% AH after trouncing estimates on 93% license growth</a></h4><ul>\n<li>Tableau's (NYSE:<a href=\"https://seekingalpha.com/symbol/DATA\" title=\"Tableau Software\">DATA</a>) Q4 revenue and EPS ($81.5M and $0.20) respectively beat consensus forecasts by $14.5M and $0.20. Y/Y revenue growth accelerated to 95% from Q3's 90%.</li>\n<li>License revenue (71% of total revenue, drives future maintenance revenue) grew 93%, up from Q3's 90%. Maintenance revenue (29% of total) doubled to $23.4M after growing 91% in Q3.</li>\n<li>The data visualization/analytics upstart added 1,800+ customers and closed 179 $100K+ deals in seasonally strong Q4, up from 1,500+ and 119 in Q3. The company's deferred revenue balance rose 28% Q/Q to $69.2M.</li>\n<li>Like many fast-growing enterprise software names, Tableau continues to invest aggressively: sales/marketing spend rose 73% Y/Y to $40.1M, and R&amp;D spend 76% to $18.4M.</li>\n<li>Rival <a href=\"https://seekingalpha.com/symbol/QLIK\" title=\"Qlik Technologies Inc.\">QLIK</a> <font color=\"green\">+1.3%</font> AH. The company reports on Feb. 20. Tableau's license numbers stands in stark contrast to the Y/Y license revenue decline rival Tibco (NASDAQ:<a href=\"https://seekingalpha.com/symbol/TIBX\" title=\"TIBCO Software, Inc.\">TIBX</a>) reported for its Spotfire analytics platform for the November quarter.</li>\n<li>\n<a href=\"http://event.on24.com/r.htm?e=733991&amp;s=1&amp;k=7E28E479FBB4CC73A7C88FCC954CB795\" target=\"_blank\">CC</a> at 5PM ET. <a href=\"https://seekingalpha.com/news/1547561-tableau-software\" target=\"_blank\">Q4 results</a>, PR.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1547931\" data-linked=\"Tableau +14.2% AH after trouncing estimates on 93% license growth\" data-tweet=\"$DATA $DATA $QLIK - Tableau +14.2% AH after trouncing estimates on 93% license growth https://seekingalpha.com/news/1547931-tableau-plus-14_2-percent-ah-after-trouncing-estimates-on-93-percent-license-growth?source=tweet\" data-url=\"https://seekingalpha.com/news/1547931-tableau-plus-14_2-percent-ah-after-trouncing-estimates-on-93-percent-license-growth\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1547871\" data-ts=\"1391549199\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GIMO\" target=\"_blank\">GIMO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1547871-gigamon-inc-beats-by-0_16-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gigamon, Inc. beats by $0.16, beats on revenue</a></h4><ul>\n<li>Gigamon, Inc. (NYSE:<a href=\"https://seekingalpha.com/symbol/GIMO\" title=\"Gigamon, Inc.\">GIMO</a>): Q4 EPS of $0.28 <font color=\"green\">beats by $0.16</font>.</li>\n<li>Revenue of $43.1M (+35.1% Y/Y) <font color=\"green\">beats by $1.12M</font>.</li>\n<li>Shares <font color=\"green\">+3.6%</font>.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1547871\" data-linked=\"Gigamon, Inc. beats by $0.16, beats on revenue\" data-tweet=\"$GIMO - Gigamon, Inc. beats by $0.16, beats on revenue https://seekingalpha.com/news/1547871-gigamon-inc-beats-by-0_16-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/1547871-gigamon-inc-beats-by-0_16-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:26 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1547851\" data-ts=\"1391549081\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/USNA\" target=\"_blank\">USNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1547851-usana-health-sciences-inc-beats-by-0_21-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">USANA Health Sciences, Inc beats by $0.21, beats on revenue</a></h4><ul>\n<li>USANA Health Sciences, Inc (NYSE:<a href=\"https://seekingalpha.com/symbol/USNA\" title=\"USANA Health Sciences Inc.\">USNA</a>): Q4 EPS of $1.41 <font color=\"green\">beats by $0.21</font>.</li>\n<li>Revenue of $186.3M (+10.5% Y/Y) <font color=\"green\">beats by $10.77M</font>.</li>\n<li>Shares <font color=\"green\">+10.2%</font>.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1547851\" data-linked=\"USANA Health Sciences, Inc beats by $0.21, beats on revenue\" data-tweet=\"$USNA - USANA Health Sciences, Inc beats by $0.21, beats on revenue https://seekingalpha.com/news/1547851-usana-health-sciences-inc-beats-by-0_21-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/1547851-usana-health-sciences-inc-beats-by-0_21-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:24 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1547661\" data-ts=\"1391548417\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OCLR\" target=\"_blank\">OCLR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1547661-oclaro-inc-misses-by-0_02-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oclaro, Inc. misses by $0.02, beats on revenue</a></h4><ul>\n<li>Oclaro, Inc. (NASDAQ:<a href=\"https://seekingalpha.com/symbol/OCLR\" title=\"Oclaro, Inc.\">OCLR</a>): FQ2 EPS of $-0.29 <font color=\"red\">misses by $0.02</font>.</li>\n<li>Revenue of $102.9M (-35.5% Y/Y) <font color=\"green\">beats by $4.87M</font>.</li>\n<li>Shares <font color=\"green\">+1.6%</font>.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1547661\" data-linked=\"Oclaro, Inc. misses by $0.02, beats on revenue\" data-tweet=\"$OCLR - Oclaro, Inc. misses by $0.02, beats on revenue https://seekingalpha.com/news/1547661-oclaro-inc-misses-by-0_02-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/1547661-oclaro-inc-misses-by-0_02-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:13 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1547571\" data-ts=\"1391548215\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IDRA\" target=\"_blank\">IDRA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1547571-idera-announces-stock-offering-shares-minus-4_8-percent-ah\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Idera announces stock offering, shares -4.8% AH</a></h4><ul>\n<li>Idera Pharmaceuticals (NASDAQ:<a href=\"https://seekingalpha.com/symbol/IDRA\" title=\"Idera Pharmaceuticals, Inc.\">IDRA</a>) has announced a stock offering of undisclosed size. Shares are selling off in response.</li>\n<li>The offering comes with Idera shares up over 5x from where they started 2013. Idera had $39.1M in cash/equivalents at the end of September, and no debt.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1547571\" data-linked=\"Idera announces stock offering, shares -4.8% AH\" data-tweet=\"$IDRA - Idera announces stock offering, shares -4.8% AH https://seekingalpha.com/news/1547571-idera-announces-stock-offering-shares-minus-4_8-percent-ah?source=tweet\" data-url=\"https://seekingalpha.com/news/1547571-idera-announces-stock-offering-shares-minus-4_8-percent-ah\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1547461\" data-ts=\"1391547774\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BWLD\" target=\"_blank\">BWLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1547461-buffalo-wild-wings-inc-beats-by-0_03-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Buffalo Wild Wings, Inc. beats by $0.03, misses on revenue</a></h4><ul>\n<li>Buffalo Wild Wings, Inc. (<a href=\"https://seekingalpha.com/symbol/BWLD\" title=\"Buffalo Wild Wings, Inc.\">BWLD</a>): Q4 EPS of $1.10 <font color=\"green\">beats by $0.03</font>.</li>\n<li>Revenue of $341.5M (+12.4% Y/Y) <font color=\"red\">misses by $5.35M</font>.</li>\n<li>Shares <font color=\"green\">+4.6%</font>.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1547461\" data-linked=\"Buffalo Wild Wings, Inc. beats by $0.03, misses on revenue\" data-tweet=\"$BWLD - Buffalo Wild Wings, Inc. beats by $0.03, misses on revenue https://seekingalpha.com/news/1547461-buffalo-wild-wings-inc-beats-by-0_03-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/1547461-buffalo-wild-wings-inc-beats-by-0_03-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1547411\" data-ts=\"1391547576\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/REXX\" target=\"_blank\">REXX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1547411-rex-energy-plus-2_2-percent-on-increases-in-oil-gas-reserves\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rex Energy +2.2% on increases in oil, gas reserves</a></h4><ul>     <li>Rex Energy (<a href=\"https://seekingalpha.com/symbol/REXX\" title=\"Rex Energy Corporation\">REXX</a> <font color=\"green\">+2.2%</font>) says its proven oil and natural gas reserves of 849.8B cfe as of Dec. 31 are 37% higher than a year earlier; of that total, 39% was attributable to oil, natural gas liquids and  condensate.</li>\n<li>Rex says the reconciled price of proved reserves between  Dec. 31, 2012, and Dec. 31, 2013, was $93.42/bbl of oil and  natural gas liquids and $3.67/mBtu for  natural gas, adjusted for contractual agreements.</li>\n<li>Rex  says it replaced 923% of its production of  ~33,850M cfe for  FY 2013 with a proved  reserves-to-production  ratio of 25.1 years.</li>      </ul><div class=\"tiny-share-widget\" data-id=\"1547411\" data-linked=\"Rex Energy +2.2% on increases in oil, gas reserves\" data-tweet=\"$REXX - Rex Energy +2.2% on increases in oil, gas reserves https://seekingalpha.com/news/1547411-rex-energy-plus-2_2-percent-on-increases-in-oil-gas-reserves?source=tweet\" data-url=\"https://seekingalpha.com/news/1547411-rex-energy-plus-2_2-percent-on-increases-in-oil-gas-reserves\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:59 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1547391\" data-ts=\"1391547077\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FURX\" target=\"_blank\">FURX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1547391-furiex-pharma-target-raised-to-137-at-ladenburg-after-positive-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Furiex Pharma target raised to $137 at Ladenburg after positive data</a></h4><ul>     <li>Ladenburg Thalmann <a href=\"http://www.streetinsider.com/Analyst+PT+Change/Furiex+Pharmaceuticals+%28FURX%29+Price+Target+Raised+to+%24137+at+Ladenburg+Thalmann/9123120.html\" target=\"_blank\">hikes its price target</a> for Furiex Pharmaceuticals (<a href=\"https://seekingalpha.com/symbol/FURX\" title=\"Furiex Pharmaceuticals, Inc.\">FURX</a> <font color=\"green\">+127.8%</font>) to $137 from $57 after the drug developer's Eluxadoline experimental drug to treat a form of irritable bowel syndrome <a href=\"https://seekingalpha.com/news/1546021-furiex-eluxadoline-trial-results-smell-great-shares-soar\" target=\"_blank\">met main goals in a late-stage study</a>.</li>     <li>Alogliptin, now approved in the U.S., Japan and Europe, represents another valuable asset, the firm says, expecting U.S. and E.U. revenues will start to impact the level of royalty revenues FURX receives during 2014; the company is entitled to tiered royalties of 8%-12% and 4%-8% in the U.S. and Europe/Japan, respectively (Briefing.com).</li>     <li>Mizuho does not consider positive data yesterday for FURX as a negative for Salix Pharma's (<a href=\"https://seekingalpha.com/symbol/SLXP\" title=\"Salix Pharmaceuticals, Ltd.\">SLXP</a> <font color=\"green\">+2.5%</font>) Xifaxan; a large population means room for two products, and different MOA and response rates mean variable patient responses, it says.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1547391\" data-linked=\"Furiex Pharma target raised to $137 at Ladenburg after positive data\" data-tweet=\"$FURX $FURX $SLXP - Furiex Pharma target raised to $137 at Ladenburg after positive data https://seekingalpha.com/news/1547391-furiex-pharma-target-raised-to-137-at-ladenburg-after-positive-data?source=tweet\" data-url=\"https://seekingalpha.com/news/1547391-furiex-pharma-target-raised-to-137-at-ladenburg-after-positive-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1547361\" data-ts=\"1391545361\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SLCA\" target=\"_blank\">SLCA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1547361-u-s-silica-minus-4_2-percent-as-jefferies-cuts-to-hold-from-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">U.S. Silica -4.2% as Jefferies cuts to Hold from Buy</a></h4><ul>     <li>U.S. Silica (<a href=\"https://seekingalpha.com/symbol/SLCA\" title=\"U.S. Silica\">SLCA</a> <font color=\"red\">-4.2%</font>) is <a href=\"http://www.streetinsider.com/Downgrades/Jefferies+Downgrades+U.S.+Silica+Holdings+%28SLCA%29+to+Hold/9120742.html\" target=\"_blank\">downgraded</a> to Hold from Buy with a $31 price target, down from $41, at Jefferies, which says frac sand demand potential does not offset execution concerns at the company.</li>\n<li>The firm says it is troubled by SLCA's lack of progress in managing logistics costs, implied  lower than expected volumes of higher-grade sand, and an apparent lack  of competitive advantage.</li>\n<li>The firm lowers its 2014 and 2015 estimated EPS to $1.85 and $2.30, respectively, from $2.35 and $3.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1547361\" data-linked=\"U.S. Silica -4.2% as Jefferies cuts to Hold from Buy\" data-tweet=\"$SLCA - U.S. Silica -4.2% as Jefferies cuts to Hold from Buy https://seekingalpha.com/news/1547361-u-s-silica-minus-4_2-percent-as-jefferies-cuts-to-hold-from-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/1547361-u-s-silica-minus-4_2-percent-as-jefferies-cuts-to-hold-from-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1547331\" data-ts=\"1391544608\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TNXP\" target=\"_blank\">TNXP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1547331-tonix-pharma-expects-results-on-fibromyalgia-test-during-h2-shares-plus-5_7-percent\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tonix Pharma expects results on fibromyalgia test during H2, shares +5.7%</a></h4><ul>     <li>Tonix Pharmaceuticals (<a href='https://seekingalpha.com/symbol/TNXP' title='Tonix Pharmaceuticals Holding Corp.'>TNXP</a> <font color='green'>+5.7%</font>) says it <a href=\"http://www.nasdaq.com/article/sector-update-healthcare%283%29-cm323538\" target=\"_blank\">expects to report results</a> from Phase IIb testing of its TNX-102 SL drug candidate in patients with fibromyalgia during H2 2014.</li>     <li>TNXP says it began enrollment in the BESTFIT trial last September which was expected to monitor ~120 patients split equally between groups receiving either TNX-102 SL or placebo, measuring changes in pain intensity.</li>     <li>TNXP also says it expects to begin a trial of TNX-102 SL as a potential treatment for post-traumatic stress disorder and tension-type headache during Q3 and Q4, respectively.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1547331\" data-linked=\"Tonix Pharma expects results on fibromyalgia test during H2, shares +5.7%\" data-tweet=\"$TNXP - Tonix Pharma expects results on fibromyalgia test during H2, shares +5.7% https://seekingalpha.com/news/1547331-tonix-pharma-expects-results-on-fibromyalgia-test-during-h2-shares-plus-5_7-percent?source=tweet\" data-url=\"https://seekingalpha.com/news/1547331-tonix-pharma-expects-results-on-fibromyalgia-test-during-h2-shares-plus-5_7-percent\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1547271\" data-ts=\"1391543489\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RGSE\" target=\"_blank\">RGSE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1547271-rgs-energy-jumps-after-announcing-150m-jv\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RGS Energy jumps after announcing $150M JV</a></h4><ul>\n<li>RGS Energy (RSOL <font color=\"green\">+8.6%</font>) is partnering with clean energy project developer Altus Power America to create a JV that will \"develop, finance and manage up to $150 million of commercial solar projects.\"</li>\n<li>RGS and Altus state the first \"fully financed projects\" stemming from the JV will be operational in Q2. RGS states the deal represents \"first foray into asset energy ownership and long-term asset management.\"</li>\n<li>Yesterday, RGS sold off hard following news it had filed a <a href=\"https://seekingalpha.com/news/1543861-rgs-energy-dives-after-filing-mixed-shelf\" target=\"_blank\">$200M mixed shelf</a>.</li>\n<li>Prior deals: <a href=\"https://seekingalpha.com/news/1490461-real-goods-solar-strikes-massachusetts-deal-shares-plus-12_2-percent-premarket\" target=\"_blank\">Massachusetts solar farms</a>, <a href=\"https://seekingalpha.com/news/1485191-real-goods-solar-rallies-again-vermont-deal-announced\" target=\"_blank\">Vermont projects</a>\n</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1547271\" data-linked=\"RGS Energy jumps after announcing $150M JV\" data-tweet=\"$RGSE - RGS Energy jumps after announcing $150M JV https://seekingalpha.com/news/1547271-rgs-energy-jumps-after-announcing-150m-jv?source=tweet\" data-url=\"https://seekingalpha.com/news/1547271-rgs-energy-jumps-after-announcing-150m-jv\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1547261\" data-ts=\"1391542965\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SA\" target=\"_blank\">SA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1547261-seabridge-gold-says-sale-of-grassy-mountain-npi-a-no-go\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Seabridge Gold says sale of Grassy Mountain NPI a no-go</a></h4><ul>     <li>Seabridge Gold (<a href=\"https://seekingalpha.com/symbol/SA\" title=\"Seabridge Gold Inc\">SA</a> <font color=\"green\">+2.2%</font>) says its agreement to sell its 10% net profits interest in the Grassy Mountain project will not proceed.</li>     <li>The sale  was conditional on the completion of the sale by Grassy Mountain owner Calico Resources to Rockstar Resources, but Calico says it did not receive the required second down payment.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1547261\" data-linked=\"Seabridge Gold says sale of Grassy Mountain NPI a no-go\" data-tweet=\"$SA - Seabridge Gold says sale of Grassy Mountain NPI a no-go https://seekingalpha.com/news/1547261-seabridge-gold-says-sale-of-grassy-mountain-npi-a-no-go?source=tweet\" data-url=\"https://seekingalpha.com/news/1547261-seabridge-gold-says-sale-of-grassy-mountain-npi-a-no-go\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:42 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1547241\" data-ts=\"1391542409\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVS\" target=\"_blank\">NVS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1547241-novartis-reportedly-draws-interest-for-vaccines-business-could-fetch-1b\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Novartis reportedly draws interest for vaccines business, could fetch $1B</a></h4><ul>     <li>Novartis (<a href=\"https://seekingalpha.com/symbol/NVS\" title=\"Novartis AG\">NVS</a> <font color=\"red\">-0.7%</font>) reportedly is <a href=\"http://www.bloomberg.com/news/2014-02-04/novartis-said-to-draw-interest-for-vaccines-business.html\" target=\"_blank\">drawing interest for its human vaccines unit</a> as talks to swap its animal health business for assets from Merck (<a href=\"https://seekingalpha.com/symbol/MRK\" title=\"Merck &amp; Co Inc.\">MRK</a> <font color=\"green\">+2.6%</font>) slow down.</li>     <li>While the vaccines unit was initially on the table with animal health as part of the possible trade for MRK\u2019s over-the-counter drugs business, NVS may now sell the vaccines unit separately in a deal that could be valued at ~$1B.</li>     <li>NVS and MRK are still talking but agreeing on valuation is proving difficult, so NVS has informally  talked to Eli Lilly (<a href=\"https://seekingalpha.com/symbol/LLY\" title=\"Eli Lilly and Company\">LLY</a> <font color=\"red\">-0.1%</font>) and Bayer (<a href=\"https://seekingalpha.com/symbol/BAYRY\" title=\"Bayer A.G. ADR\">OTCPK:BAYRY</a>, <a href=\"https://seekingalpha.com/symbol/BAYZF\" title=\"Bayer A.G.\">OTCPK:BAYZF</a>) about the animal health business, according to the report.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1547241\" data-linked=\"Novartis reportedly draws interest for vaccines business, could fetch $1B\" data-tweet=\"$NVS $NVS $MRK - Novartis reportedly draws interest for vaccines business, could fetch $1B https://seekingalpha.com/news/1547241-novartis-reportedly-draws-interest-for-vaccines-business-could-fetch-1b?source=tweet\" data-url=\"https://seekingalpha.com/news/1547241-novartis-reportedly-draws-interest-for-vaccines-business-could-fetch-1b\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:33 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1547221\" data-ts=\"1391541575\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APC\" target=\"_blank\">APC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1547221-anadarko-pushes-higher-despite-q4-miss-tronox-uncertainty\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Anadarko pushes higher despite Q4 miss, Tronox uncertainty</a></h4><ul>     <li>Anadarko Petroleum (<a href=\"https://seekingalpha.com/symbol/APC\" title=\"Anadarko Petroleum Corporation\">APC</a> <font color=\"green\">+2.3%</font>) is on the rise despite <a href=\"https://seekingalpha.com/news/1545171-anadarko-reports-loss-as-it-braces-for-tronox-payment\" target=\"_blank\">missing its earnings</a> number, and Jefferies analysts explain why the miss <a href=\"http://blogs.barrons.com/stockstowatchtoday/2014/02/04/anadarko-its-still-about-its-tronox-liabilities\" target=\"_blank\">isn't a big deal</a>.</li>\n<li>The EPS miss was driven by exploration expense that was $300M more than expected, but production was ahead of guidance, as oil, gas and NGL volumes all beat estimates, the firm says.</li>\n<li>DD&amp;A was significantly lower than forecast, and cash costs came in lower than expected; pricing was roughly in line on a blended basis, and NGL pricing was strong, with realizations of over $40/bbl.</li>\n<li>However, J.P. Morgan finds APC\u2019s handling of the Tronox liabilities curious, noting that its given range of probable losses do not include possible interest, attorneys\u2019 fees or other costs, which could be material; in the case of a settlement, APC expects the payment would be substantially greater than the $850M accrual.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1547221\" data-linked=\"Anadarko pushes higher despite Q4 miss, Tronox uncertainty\" data-tweet=\"$APC - Anadarko pushes higher despite Q4 miss, Tronox uncertainty https://seekingalpha.com/news/1547221-anadarko-pushes-higher-despite-q4-miss-tronox-uncertainty?source=tweet\" data-url=\"https://seekingalpha.com/news/1547221-anadarko-pushes-higher-despite-q4-miss-tronox-uncertainty\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:19 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1547161\" data-ts=\"1391538741\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JCP\" target=\"_blank\">JCP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1547161-j-c-penney-on-the-5-and-below-rack\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">J.C. Penney on the $5 and below rack</a></h4><ul> <li>Shares of J.C. Penney (<a href=\"https://seekingalpha.com/symbol/JCP\" title=\"J.C. Penney Company Inc.\">JCP</a> <font color=\"red\">-10.9%</font>) fall below $5 on extremely heavy volume after the company's report on sales causes a selling panic.</li> <li>Though the comp came in positive for a change, it was only about half the rate that analysts forecast.</li> <li>The company declined on delivering a portion of the bad news (November and December) when it updated guidance on January 4 with a terse 38-word PR, but had to deliver the goods today.</li> <li>Previous: <a href=\"https://seekingalpha.com/news/1546941-analysts-weigh-in-on-j-c-penneys-sales-track\" target=\"_blank\">Analysts warn on JCP</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1547161\" data-linked=\"J.C. Penney on the $5 and below rack\" data-tweet=\"$JCP - J.C. Penney on the $5 and below rack https://seekingalpha.com/news/1547161-j-c-penney-on-the-5-and-below-rack?source=tweet\" data-url=\"https://seekingalpha.com/news/1547161-j-c-penney-on-the-5-and-below-rack\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1547151\" data-ts=\"1391538721\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PANW\" target=\"_blank\">PANW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1547151-palo-alto-receives-pac-crest-pt-hike-partners-with-citrix-to-challenge-f5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Palo Alto receives Pac Crest PT hike, partners with Citrix to challenge F5</a></h4><ul>\n<li>A day after Wells Fargo upgraded Palo Alto Networks (<a href=\"https://seekingalpha.com/symbol/PANW\" title=\"Palo Alto Networks\">PANW</a> <font color=\"green\">+5%</font>) to Outperform, Pac Crest has hiked its PT to $75 from $65, while reiterating an Outperform.</li>\n<li>The note, which comes 20 days before Palo Alto's FQ2 report, has helped shares move back above $60. They <a href=\"https://seekingalpha.com/news/1451941-bullish-pac-crest-note-helps-palo-alto-continue-fall-rally\" target=\"_blank\">also rallied</a> in December in response to an upbeat Pac Crest note.</li>\n<li>Separately, Palo Alto and Citrix (<a href=\"https://seekingalpha.com/symbol/CTXS\" title=\"Citrix Systems, Inc.\">CTXS</a> <font color=\"green\">+1.1%</font>) have announced an expansion of their security/networking partnership (<a href=\"https://seekingalpha.com/news/568181\" target=\"_blank\">previous</a>). Citrix's <a href=\"http://www.citrix.com/products/netscaler-application-delivery-controller/features/platforms/sdx.html\" target=\"_blank\">NetScaler SDX </a>application delivery controllers (ADCs - they analyze Web traffic at the application level and direct it to/from servers) will now support \"virtual\" instances of Palo Alto's next-gen firewalls.</li>\n<li>The companies note different instances of Palo Alto's  virtual firewall products, known as the <a href=\"https://www.paloaltonetworks.com/products/platforms/virtualized-firewalls/vm-series/overview.html\" target=\"_blank\">VM-Series</a>, can be tailored to the needs of different apps when placed within a Citrix ADC. The firewalls still leverage Palo Alto's proprietary PAN-OS operating system.</li>\n<li>The partnership is aimed in part at F5 (<a href=\"https://seekingalpha.com/symbol/FFIV\" title=\"F5 Networks, Inc.\">FFIV</a> <font color=\"green\">+1.4%</font>). F5 has launched <a href=\"https://f5.com/products/modules/advanced-firewall-manager\" target=\"_blank\">firewall</a> and <a href=\"https://f5.com/products/modules/application-security-manager\" target=\"_blank\">app security</a> modules for its market-leading ADCs, and is attempting to grab security share from incumbents with the help of its <a href=\"https://devcentral.f5.com/articles/the-full-proxy-data-center-architecture#.UvExAjJ7vh4\" target=\"_blank\">full-proxy architecture</a>.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1547151\" data-linked=\"Palo Alto receives Pac Crest PT hike, partners with Citrix to challenge F5\" data-tweet=\"$PANW $PANW $CTXS - Palo Alto receives Pac Crest PT hike, partners with Citrix to challenge F5 https://seekingalpha.com/news/1547151-palo-alto-receives-pac-crest-pt-hike-partners-with-citrix-to-challenge-f5?source=tweet\" data-url=\"https://seekingalpha.com/news/1547151-palo-alto-receives-pac-crest-pt-hike-partners-with-citrix-to-challenge-f5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1547071\" data-ts=\"1391536105\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARCH\" target=\"_blank\">ARCH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1547071-arch-coal-turns-around-after-optimistic-comments-about-2014-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arch Coal turns around after optimistic comments about 2014 outlook</a></h4><ul>     <li>Arch Coal (<a href=\"https://seekingalpha.com/symbol/ACI\" title=\"Albertsons Companies Inc\">ACI</a> <font color=\"green\">+2%</font>) shares turn green after management makes <a href=\"http://www.theflyonthewall.com/permalinks/entry.php/ACI;CLD;WLT;BTU;ARLP;CNX;ANRid1957212/ACI;CLD;WLT;BTU;ARLP;CNX;ANR-Arch-Coal-climbs-after-optimistic-comments-about--outlook\" target=\"_blank\">positive comments</a> about the thermal coal market during this morning's earnings call.</li>     <li>ACI reported a larger than expected <a href=\"https://seekingalpha.com/news/1546421-arch-coal-minus-3_7-percent-after-bigger-than-expected-q4-loss-on-weak-sales\" target=\"_blank\">Q4 loss</a>, but expects U.S. thermal coal markets to tighten further this year, as several factors including favorable weather trends, healthier economic activity and elevated natural gas prices should ensure that the prices of most U.S. thermal coal is competitive.</li>\n<li>The same can't be said for metallurgical coal, as overseas markets remain weak, ACI says, but production of higher cost met coal would ease and cause markets to tighten in the future.</li>\n<li>Other coal miners also are higher: <a href=\"https://seekingalpha.com/symbol/CLD\" title=\"Cloud Peak Energy, Inc.\">CLD</a> <font color=\"green\">+3.9%</font>, <a href=\"https://seekingalpha.com/symbol/WLT\" title=\"Walter Energy, Inc.\">WLT</a> <font color=\"green\">+3.7%</font>, <a href=\"https://seekingalpha.com/symbol/WLB\" title=\"Westmoreland Coal Co\">WLB</a> <font color=\"green\">+3.4%</font>, ANR <font color=\"green\">+2.6%</font>, <a href=\"https://seekingalpha.com/symbol/RNO\" title=\"Rhino Resource Partners LP\">RNO</a> <font color=\"green\">+2.1%</font>, <a href=\"https://seekingalpha.com/symbol/CNX\" title=\"CNX Resources Corporation\">CNX</a> <font color=\"green\">+1.5%</font>, <a href=\"https://seekingalpha.com/symbol/BTU\" title=\"Peabody Energy Corp.\">BTU</a> <font color=\"green\">+0.2%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1547071\" data-linked=\"Arch Coal turns around after optimistic comments about 2014 outlook\" data-tweet=\"$ARCH $ARCH $CLDPQ - Arch Coal turns around after optimistic comments about 2014 outlook https://seekingalpha.com/news/1547071-arch-coal-turns-around-after-optimistic-comments-about-2014-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/1547071-arch-coal-turns-around-after-optimistic-comments-about-2014-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1547061\" data-ts=\"1391536019\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1547061-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li>\n<b>Top 10 Gainers:</b>  <a href=\"https://seekingalpha.com/symbol/LIOX\" title=\"Lionbridge Technologies, Inc.\">LIOX</a> <font color=\"green\">+25%</font>. <a href=\"https://seekingalpha.com/symbol/ATMI\" title=\"ATMI Inc.\">ATMI</a> <font color=\"green\">+26%</font>. <a href=\"https://seekingalpha.com/symbol/NLST\" title=\"Netlist, Inc.\">OTC:NLST</a> <font color=\"green\">+23%</font>. KORS <font color=\"green\">+18%</font>. <a href=\"https://seekingalpha.com/symbol/HW\" title=\"Headwaters Incorporated\">HW</a> <font color=\"green\">+17%</font>. <a href=\"https://seekingalpha.com/symbol/NIHD\" title=\"NII Holdings, Inc.\">NIHD</a> <font color=\"green\">+14%</font>. <a href=\"https://seekingalpha.com/symbol/IDTI\" title=\"Integrated Device Technology, Inc.\">IDTI</a> <font color=\"green\">+14%</font>. <a href=\"https://seekingalpha.com/symbol/INPH\" title=\"Interphase Corporation\">INPH</a> <font color=\"green\">+13%</font>. <a href=\"https://seekingalpha.com/symbol/QCCO\" title=\"QC Holdings, Inc.\">OTC:QCCO</a> <font color=\"green\">+13%</font>.</li>\n<li>\n<b>Top 10 Losers:</b> <a href=\"https://seekingalpha.com/symbol/AFOP\" title=\"Alliance Fiber Optic Products, Inc.\">AFOP</a> <font color=\"red\">-22%</font>. <a href=\"https://seekingalpha.com/symbol/KONE\" title=\"Kingtone Wirelessinfo Solution Holding Ltd\">KONE</a> <font color=\"red\">-18%</font>. <a href=\"https://seekingalpha.com/symbol/PSMI\" title=\"Peregrine Semiconductor\">PSMI</a> <font color=\"red\">-17%</font>. <a href=\"https://seekingalpha.com/symbol/PCYG\" title=\"Park City Group, Inc.\">PCYG</a> <font color=\"red\">-15%</font>. <a href=\"https://seekingalpha.com/symbol/ORMP\" title=\"Oramed Pharmaceuticals Inc.\">ORMP</a> <font color=\"red\">-8%</font>. <a href=\"https://seekingalpha.com/symbol/STLY\" title=\"HG Holdings Inc\">STLY</a> <font color=\"red\">-12%</font>. <a href=\"https://seekingalpha.com/symbol/LIVE\" title=\"Live Ventures\">LIVE</a> <font color=\"red\">-10%</font>. <a href=\"https://seekingalpha.com/symbol/FN\" title=\"Fabrinet\">FN</a> <font color=\"red\">-10%</font>. <a href=\"https://seekingalpha.com/symbol/GDOT\" title=\"Green Dot Corporation\">GDOT</a> <font color=\"red\">-9%</font>. <a href=\"https://seekingalpha.com/symbol/TTWO\" title=\"Take-Two Interactive Software, Inc.\">TTWO</a> <font color=\"red\">-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1547061\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$LIOX $ATMI $NLST - Midday Gainers / Losers https://seekingalpha.com/news/1547061-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/1547061-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1547051\" data-ts=\"1391535452\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNE\" target=\"_blank\">SNE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1547051-sony-reportedly-in-talks-to-sell-pc-ops-shares-jump\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sony reportedly in talks to sell PC ops, shares jump</a></h4><ul><li>The <em>Nikkei</em> reports Sony (<a href='https://seekingalpha.com/symbol/SNE' title='Sony Corporation'>SNE</a> <font color='green'>+5.1%</font>) is in talks to sell its Vaio PC unit, and is looking to receive &yen;40B-&yen;50B ($394M-$492M).</li><li>The report follows one <a href=\"https://seekingalpha.com/news/1542201-sony-mulls-options-for-pc-ops\" target=\"_blank\">over the weekend</a> stating Lenovo (<a href='https://seekingalpha.com/symbol/LNVGY' title='Lenovo Group Ltd. ADR'>OTCPK:LNVGY</a>), which last month struck deals to buy Motorola Mobility and IBM's x86 server unit, is in talks to acquire Sony's PC ops. Sony called the report inaccurate, but admitted it's exploring options for the business.</li><li>Sony shares have shot higher on the <em>Nikkei</em>'s report. Investors like the idea of unloading a loss-generating unit that has struggled to deal with <a href=\"https://seekingalpha.com/news/1501281-pc-shipment-declines-narrow-further-in-q4-lenovo-and-dell-take-share\" target=\"_blank\">declining PC sales</a> and tough competition from Lenovo, H-P, and others. The company's FQ3 report is due on Thursday morning.</li><li>Thanks to both the Sony report and a massive equity selloff, Lenovo shares are <font color='red'>down 16%</font> in Hong Kong over the last two days.</li></ul><div class=\"tiny-share-widget\" data-id=\"1547051\" data-linked=\"Sony reportedly in talks to sell PC ops, shares jump\" data-tweet=\"$SNE $SNE $LNVGY - Sony reportedly in talks to sell PC ops, shares jump https://seekingalpha.com/news/1547051-sony-reportedly-in-talks-to-sell-pc-ops-shares-jump?source=tweet\" data-url=\"https://seekingalpha.com/news/1547051-sony-reportedly-in-talks-to-sell-pc-ops-shares-jump\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1547001\" data-ts=\"1391535081\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OAS\" target=\"_blank\">OAS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1547001-oasis-petroleum-minus-5_2-percent-as-big-2014-production-goals-mean-big-spending\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oasis Petroleum -5.2% as big 2014 production goals mean big spending</a></h4><ul>     <li>Investors aren't happy with Oasis Petroleum's (<a href=\"https://seekingalpha.com/symbol/OAS\" title=\"Oasis Petroleum Inc.\">OAS</a> <font color=\"red\">-5.2%</font>) plans to increase spending significantly this year to ramp up production.</li>     <li>OAS plans to spend $1.43B in 2014, a 40% Y/Y increase, to achieve its goal of producing 46K-50K boe/day from 33,904 boe/day in 2013.</li>\n<li>For the year, OAS expects to complete 205 Bakken wells, up from 136 last year.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1547001\" data-linked=\"Oasis Petroleum -5.2% as big 2014 production goals mean big spending\" data-tweet=\"$OAS - Oasis Petroleum -5.2% as big 2014 production goals mean big spending https://seekingalpha.com/news/1547001-oasis-petroleum-minus-5_2-percent-as-big-2014-production-goals-mean-big-spending?source=tweet\" data-url=\"https://seekingalpha.com/news/1547001-oasis-petroleum-minus-5_2-percent-as-big-2014-production-goals-mean-big-spending\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1546991\" data-ts=\"1391535039\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVCN\" target=\"_blank\">NVCN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1546991-neovasc-soars-again-following-successful-tiara-implant\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Neovasc soars again following successful Tiara implant</a></h4><ul>\n<li>Neovasc (NVCIF <font color=\"green\">+45.6%</font>) rockets higher for a 2nd consecutive session after <a href=\"http://www.neovasc.com/wp-content/uploads/2014/02/Neovasc_Tiara_First_in_Human.pdf\" target=\"_blank\">yesterday reporting</a> the successful transplantation of its Tiara valve in a 73 year-old male patient.</li>\n<li>\"The transapical implantation of the Tiara valve was completed quickly and without complications. It resulted in a well-functioning bioprosthetic valve with no significant paravalvular leak or residual MR,\" says the surgeon who performed the procedure.</li>\n<li>Kudos to SA Pro's Matthew Charles Fox who has been all over the Neovasc story since late October. <a href=\"https://seekingalpha.com/article/1991391-neovasc-inc-part-iii-an-undiscovered-gem-in-the-medical-device-industry\" target=\"_blank\">His latest piece</a> from today explains why he's still a buyer after a more than doubling in the stock price since his initial recommendation.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1546991\" data-linked=\"Neovasc soars again following successful Tiara implant\" data-tweet=\"$NVCN - Neovasc soars again following successful Tiara implant https://seekingalpha.com/news/1546991-neovasc-soars-again-following-successful-tiara-implant?source=tweet\" data-url=\"https://seekingalpha.com/news/1546991-neovasc-soars-again-following-successful-tiara-implant\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:30 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1546971\" data-ts=\"1391534473\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WETF\" target=\"_blank\">WETF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1546971-wisdomtree-boosted-by-baml\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WisdomTree boosted by BAML</a></h4><ul>\n<li>WisdomTree's (NASDAQ:<a href=\"https://seekingalpha.com/symbol/WETF\" title=\"WisdomTree Investments, Inc.\">WETF</a>) big decline thus far this year (after a major run higher in 2013) brings out a buyer as <a href=\"http://www.streetinsider.com/Upgrades/BofAMerrill+Lynch+Upgrades+WisdomTree+Investments+%28WETF%29+to+Buy/9120782.html\" target=\"_blank\">BAML upgrades</a> the stock to a Buy with $17 price target.</li>\n<li>In other sell-side news, Jefferies cuts its earnings estimates, but retains a Buy rating and $18 price target.</li>\n<li>The stock's <font color=\"green\">ahead 8%</font> on the session.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1546971\" data-linked=\"WisdomTree boosted by BAML\" data-tweet=\"$WETF - WisdomTree boosted by BAML https://seekingalpha.com/news/1546971-wisdomtree-boosted-by-baml?source=tweet\" data-url=\"https://seekingalpha.com/news/1546971-wisdomtree-boosted-by-baml\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:21 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1546961\" data-ts=\"1391534183\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GILD\" target=\"_blank\">GILD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1546961-gilead-sciences-upgraded-at-baird-as-sovaldi-looks-like-a-blockbuster\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gilead Sciences upgraded at Baird as Sovaldi looks like a blockbuster</a></h4><ul>     <li>Gilead Sciences (<a href=\"https://seekingalpha.com/symbol/GILD\" title=\"Gilead Sciences, Inc.\">GILD</a> <font color=\"green\">+3.7%</font>) is <a href=\"http://blogs.barrons.com/stockstowatchtoday/2014/02/04/gilead-sciences-sovaldi-a-blockbuster-baird-sees-30-upside/\" target=\"_blank\">upgraded</a> to Outperform from Market Perform with a $103 price target, up from $65, at Baird even after shares have nearly doubled in the past year.</li>\n<li>Initial prescription data for sales of hepatitis C drug Sovaldi are so massively outperforming even the biggest weeks Vertex's Incivek ever had, the firm believes any reasonable comparison between the two drugs would indicate that U.S. sales in 2014 alone will exceed $5B; Sovaldi also enjoys a ~70% price premium over Incivek.</li>\n<li>Even competition with Abbvie (NYSE:<a href=\"https://seekingalpha.com/symbol/ABBV\" title=\"AbbVie Inc.\">ABBV</a>) is positive because the data justifies some meaningful penetration by Abbvie\u2019s regimen without having to resort to price as a lever, the firm adds.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1546961\" data-linked=\"Gilead Sciences upgraded at Baird as Sovaldi looks like a blockbuster\" data-tweet=\"$GILD $GILD $ABBV - Gilead Sciences upgraded at Baird as Sovaldi looks like a blockbuster https://seekingalpha.com/news/1546961-gilead-sciences-upgraded-at-baird-as-sovaldi-looks-like-a-blockbuster?source=tweet\" data-url=\"https://seekingalpha.com/news/1546961-gilead-sciences-upgraded-at-baird-as-sovaldi-looks-like-a-blockbuster\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1546921\" data-ts=\"1391533209\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1546921-natural-gas-soaring-again\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Natural gas soaring again</a></h4><ul>\n<li>Natural gas (<a href=\"https://seekingalpha.com/symbol/ung\" title=\"The United States Natural Gas ETF, LP\">UNG</a> <font color=\"green\">+6.5%</font>) is <a href=\"http://blogs.barrons.com/focusonfunds/2014/02/04/natural-gas-surges-7-hot-money-and-cold-weather/\" target=\"_blank\">flying today</a> amid a brutal winter in much of the country that just won't quit, and ahead of Thursday's supply numbers which are expected to show another near-record draw on storage.</li>\n<li>There's also bottleneck issues in some of the Northeast, especially curious given the Marcellus production boom is nearby. Production growth from Marcellus reached 4 Bcf/day in 2013, but consumer prices have barely benefited (gone lower), notes the team at Goldman.</li>\n<li>Related ETFs: <a href=\"https://seekingalpha.com/symbol/ung\" title=\"The United States Natural Gas ETF, LP\">UNG</a>, <a href=\"https://seekingalpha.com/symbol/ugaz\" title=\"VelocityShares 3x Long Natural Gas ETN\">UGAZ</a>, <a href=\"https://seekingalpha.com/symbol/gaz\" title=\"iPath DJ-UBS Natural Gas Total Return Sub-Index ETN\">GAZ</a>, <a href=\"https://seekingalpha.com/symbol/dgaz\" title=\"VelocityShares 3x Inverse Natural Gas ETN\">DGAZ</a>, <a href=\"https://seekingalpha.com/symbol/boil\" title=\"ProShares Ultra DJ-UBS Natural Gas ETF\">BOIL</a>, <a href=\"https://seekingalpha.com/symbol/unl\" title=\"The United States 12 Month Natural Gas ETF, LP\">UNL</a>, <a href=\"https://seekingalpha.com/symbol/kold\" title=\"ProShares UltraShort DJ-UBS Natural Gas ETF\">KOLD</a>, <a href=\"https://seekingalpha.com/symbol/nags\" title=\"Teucrium Natural Gas ETF\">NAGS</a>, <a href=\"https://seekingalpha.com/symbol/dcng\" title=\"iPath Pure Beta Seasonal Natural Gas ETN\">DCNG</a>\n</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1546921\" data-linked=\"Natural gas soaring again\" data-tweet=\"$UNG $UGAZ $GAZ-OLD - Natural gas soaring again https://seekingalpha.com/news/1546921-natural-gas-soaring-again?source=tweet\" data-url=\"https://seekingalpha.com/news/1546921-natural-gas-soaring-again\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1546911\" data-ts=\"1391532829\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLUG\" target=\"_blank\">PLUG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1546911-more-upside-ahead-for-plug-power-cowen-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More upside ahead for Plug Power, Cowen says</a></h4><ul>     <li>Plug Power (<a href=\"https://seekingalpha.com/symbol/PLUG\" title=\"Plug Power, Inc.\">PLUG</a> <font color=\"green\">+3.3%</font>) <a href=\"http://www.marketwatch.com/story/analysts-see-upswing-for-plug-power-2014-02-04\" target=\"_blank\">could turn profitable by the end of the year</a> and an expansion to Asia could drive upside, Cowen analysts say.</li>     <li>The firm visited Plug\u2019s factor last week and says the visit highlighted Plug\u2019s competitive  advantages and preparations for ramping up productivity, seeing lower costs and shorter lead times under a more compact hydrogen system.</li>\n<li>The analysts expect sales growth of 68% through 2018, driven by more penetration in the U.S. and Europe as well as possible expansion to Asia.</li>\n<li>Shares are up 89% YTD and up nearly 600% in the past 12 months.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1546911\" data-linked=\"More upside ahead for Plug Power, Cowen says\" data-tweet=\"$PLUG - More upside ahead for Plug Power, Cowen says https://seekingalpha.com/news/1546911-more-upside-ahead-for-plug-power-cowen-says?source=tweet\" data-url=\"https://seekingalpha.com/news/1546911-more-upside-ahead-for-plug-power-cowen-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1546901\" data-ts=\"1391532677\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGNC\" target=\"_blank\">AGNC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1546901-analysts-question-agnc-strategy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analysts question AGNC strategy</a></h4><ul>\n<li>Addressing an analyst cadre somewhat uncomfortable with American Capital's (<a href=\"https://seekingalpha.com/symbol/AGNC\" title=\"AGNC Investment Corp.\">AGNC</a> <font color=\"green\">+1.6%</font>) new policy of purchasing the common stock of <a href=\"https://seekingalpha.com/news/1546841-kain-buying-stock-of-other-mreits\" target=\"_blank\">its agency mREIT competitors</a> (Wells' Joel Houck: Do you know their hedging strategies? What happens when one blows up?), CIO Gary Kain says the discounts to asset value are so great as to mitigate much of the risk.</li>\n<li>Kain does acknowledge some risks though, and reminds that the purchase program is but a small slice of AGNC's overall portfolio ($400M of others' stock bought so far vs. nearly $600M of AGNC buybacks just in Q4).</li>\n<li>For now, there won't be any disclosure of which names American Capital is buying - a position also not sitting well with those on the call. Should the positions get large enough though, regulatory filings might be required.</li>\n<li>Kain also reminds that AGNC isn't just boosting risk with these purchases - instead it's selling MBS at 100 cents on the dollar to buy them back (via other mREITs) at somewhere in the area of 80 cents on the dollar.</li>\n<li>Most of the mREIT sector (<a href=\"https://seekingalpha.com/symbol/REM\" title=\"iShares Mortgage Real Estate Capped ETF\">REM</a> <font color=\"green\">+0.7%</font>) is ahead again today - Armour (<a href=\"https://seekingalpha.com/symbol/ARR\" title=\"ARMOUR Residential REIT, Inc.\">ARR</a> <font color=\"green\">+0.9%</font>), CYS (<a href=\"https://seekingalpha.com/symbol/CYS\" title=\"CYS Investments, Inc.\">CYS</a> <font color=\"green\">+2.8%</font>), Hatteras (<a href=\"https://seekingalpha.com/symbol/HTS\" title=\"Hatteras Financial Corp.\">HTS</a> <font color=\"green\">+1.6%</font>), American Capital Mortgage (<a href=\"https://seekingalpha.com/symbol/MTGE\" title=\"MTGE Investment Corp.\">MTGE</a> <font color=\"green\">+0.6%</font>), PennyMac (<a href=\"https://seekingalpha.com/symbol/PMT\" title=\"PennyMac Mortgage Investment Trust\">PMT</a> <font color=\"green\">+1.2%</font>) - but Annaly (<a href=\"https://seekingalpha.com/symbol/NLY\" title=\"Annaly Capital Management, Inc.\">NLY</a> <font color=\"red\">-0.6%</font>) lags, perhaps as investors feel it was far more conservatively positioned going into 2014 than AGNC was.</li>\n<li>\n<a href=\"http://edge.media-server.com/m/p/tqe5uc6z/lan/en\" target=\"_blank\">Earnings call</a> is still ongoing</li>\n<li><a href=\"https://seekingalpha.com/symbol/AGNC/news/earnings\" target=\"_blank\">Previous coverage</a></li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1546901\" data-linked=\"Analysts question AGNC strategy\" data-tweet=\"$AGNC $AGNC $REM - Analysts question AGNC strategy https://seekingalpha.com/news/1546901-analysts-question-agnc-strategy?source=tweet\" data-url=\"https://seekingalpha.com/news/1546901-analysts-question-agnc-strategy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1546881\" data-ts=\"1391532261\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ENB\" target=\"_blank\">ENB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1546881-spectra-plus-2_2-percent-as-profit-jumps-11-percent-seeks-ok-for-pipeline-extension\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Spectra +2.2% as profit jumps 11%, seeks OK for pipeline extension</a></h4><ul>     <li>Spectra Energy (<a href=\"https://seekingalpha.com/symbol/SE\" title=\"Sea Ltd\">SE</a> <font color=\"green\">+2.2%</font>) is higher after reporting its <a href=\"https://seekingalpha.com/news/1545571-spectra-energy-corp-beats-by-0_03-beats-on-revenue\" target=\"_blank\">Q4 earnings</a> rose 11% Y/Y as it completed the sale of its U.S. operations to Spectra Energy Partners (<a href=\"https://seekingalpha.com/symbol/SEP\" title=\"Spectra Energy Partners, LP\">SEP</a> <font color=\"green\">+0.7%</font>) and boosted revenue in its remaining segments.</li>     <li>Overall operating revenue jumped 16% to $1.57B, while overall operating expenses increased 11% to $1.09B.</li>     <li>Operating revenue in its western Canada  transmission and processing segment rose 22% to $533M as its Empress NGL business posted stronger earnings due to higher propane sales prices, lower costs and improved contracting structures.</li>     <li>Distribution revenue rose 12% on higher approved rates and colder weather but was weighed by a lower Canadian dollar and higher operating and fuel costs.</li>     <li>SEP's Texas Eastern subsidiary files with the FERC to <a href=\"http://finance.yahoo.com/news/spectra-seeks-ok-line-move-160155974.html\" target=\"_blank\">build a ~$468M pipeline extension</a> that would allow it to move natural gas from Ohio to the Gulf Coast.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1546881\" data-linked=\"Spectra +2.2% as profit jumps 11%, seeks OK for pipeline extension\" data-tweet=\"$ENB $ENB $SEP - Spectra +2.2% as profit jumps 11%, seeks OK for pipeline extension https://seekingalpha.com/news/1546881-spectra-plus-2_2-percent-as-profit-jumps-11-percent-seeks-ok-for-pipeline-extension?source=tweet\" data-url=\"https://seekingalpha.com/news/1546881-spectra-plus-2_2-percent-as-profit-jumps-11-percent-seeks-ok-for-pipeline-extension\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1546871\" data-ts=\"1391531347\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OPEN\" target=\"_blank\">OPEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1546871-opentable-rallies-ahead-of-earnings-on-citi-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">OpenTable rallies ahead of earnings on Citi upgrade</a></h4><ul>\n<li>Citi's <a href=\"http://www.benzinga.com/news/14/02/4279873/update-opentable-upgraded-by-citigroup-up-3\" target=\"_blank\">Mark May</a> has upgraded OpenTable (<a href=\"https://seekingalpha.com/symbol/OPEN\" title=\"OpenTable, Inc.\">OPEN</a> <font color=\"green\">+2.9%</font>) to Neutral ahead of the restaurant reservation platform's Thursday Q4 report, and raised hit PT to $74 from $68.</li>\n<li>May thinks OpenTable's results will be at least in-line, is upbeat about the company's (<a href=\"http://thenextweb.com/apps/2013/07/31/online-reservation-service-opentable-starts-testing-mobile-payments-for-diners-to-pay-checks-in-app/\" target=\"_blank\">mobile-focused</a>) product cycle, and thinks there's less near-term risk of multiple compression.</li>\n<li>Shares have gradually trended lower since soaring to new highs in November, following OpenTable's <a href=\"https://seekingalpha.com/news/1390952-new-highs-for-opentable-following-q3-beat-strong-restaurant-growth\" target=\"_blank\">market-pleasing</a> Q3 report.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1546871\" data-linked=\"OpenTable rallies ahead of earnings on Citi upgrade\" data-tweet=\"$OPEN - OpenTable rallies ahead of earnings on Citi upgrade https://seekingalpha.com/news/1546871-opentable-rallies-ahead-of-earnings-on-citi-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/1546871-opentable-rallies-ahead-of-earnings-on-citi-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1546841\" data-ts=\"1391530686\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGNC\" target=\"_blank\">AGNC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1546841-kain-buying-stock-of-other-mreits\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kain buying stock of other mREITs</a></h4><ul>\n<li>\"There are numerous reasons to believe a repeat of 2013 is not in the cards,\" says American Capital Agency (<a href=\"https://seekingalpha.com/symbol/AGNC\" title=\"AGNC Investment Corp.\">AGNC</a> <font color=\"green\">+2.2%</font>) CIO Gary Kain on the <a href=\"http://edge.media-server.com/m/p/tqe5uc6z/lan/en\" target=\"_blank\">earnings call</a>. He notes most traditional agency MBS investors are underweight the sector, and MBS have already priced in continued rises in interest rates.</li>\n<li>Not only is American Capital aggressively repurchasing its own stock while it trades at a large discount to book value, but it bought $400M worth of other agency mREIT players ($237M in Q4, increased to $400M as of the end of January). Kain: Why buy more mortgages when you can buy the companies that own them for roughly 20% less than the value of the mortgages on their books.</li>\n<li><a href=\"http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MjE4ODk5fENoaWxkSUQ9LTF8VHlwZT0z&amp;t=1\" target=\"_blank\">Earnings call slides</a></li>\n<li>Previous <a href=\"https://seekingalpha.com/symbol/AGNC/news/earnings\" target=\"_blank\">earnings coverage</a>\n</li>\n<li>Related ETFs: <a href=\"https://seekingalpha.com/symbol/REM\" title=\"iShares Mortgage Real Estate Capped ETF\">REM</a>, <a href=\"https://seekingalpha.com/symbol/MORT\" title=\"VanEck Vectors Mortgage REIT Income ETF\">MORT</a>, <a href=\"https://seekingalpha.com/symbol/MORL\" title=\"UBS ETRACS Monthly Pay 2x Leveraged Mortgage REIT ETN\">MORL</a>\n</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1546841\" data-linked=\"Kain buying stock of other mREITs\" data-tweet=\"$AGNC $AGNC $REM - Kain buying stock of other mREITs https://seekingalpha.com/news/1546841-kain-buying-stock-of-other-mreits?source=tweet\" data-url=\"https://seekingalpha.com/news/1546841-kain-buying-stock-of-other-mreits\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1546821\" data-ts=\"1391530002\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AOL\" target=\"_blank\">AOL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1546821-aol-rallies-again-money-manager-discloses-9_3-percent-stake\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AOL rallies again; money manager discloses 9.3% stake</a></h4><ul><li>Iiridian Asset Management, a firm that <a href=\"http://www.iridian.com/\" target=\"_blank\">claims to target</a> mid-cap companies \"undergoing significant corporate change,\" has disclosed a <a href=\"http://www.sec.gov/Archives/edgar/data/1033427/000103342714000015/aol13g12312013.htm\" target=\"_blank\">9.3% passive stake</a> in AOL (<a href='https://seekingalpha.com/symbol/AOL' title='AOL Inc.'>AOL</a> <font color='green'>+5.7%</font>).</li><li>Shares are adding to the gains they saw yesterday in response to a <a href=\"https://seekingalpha.com/news/1543561-aol-surges-ahead-of-earnings-on-needham-pt-hike\" target=\"_blank\">Needham PT hike</a>, and are now <font color='green'>up 7.6%</font> on the week. Q4 results arrive on Thursday morning.</li></ul><div class=\"tiny-share-widget\" data-id=\"1546821\" data-linked=\"AOL rallies again; money manager discloses 9.3% stake\" data-tweet=\"$AOL - AOL rallies again; money manager discloses 9.3% stake https://seekingalpha.com/news/1546821-aol-rallies-again-money-manager-discloses-9_3-percent-stake?source=tweet\" data-url=\"https://seekingalpha.com/news/1546821-aol-rallies-again-money-manager-discloses-9_3-percent-stake\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1546801\" data-ts=\"1391529167\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNOA\" target=\"_blank\">SNOA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1546801-oculus-innovative-sciences-plus-2_5-percent-on-european-ce-mark-for-microcyn\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oculus Innovative Sciences +2.5% on European CE Mark for Microcyn</a></h4><ul>     <li>Oculus Innovative Sciences (OCLS <font color=\"green\">+2.5%</font>) says it received the European CE Mark for its Microcyn-based GramaDerm  solution and GramaDerm hydrogel, OCLS' two products intended for use in the topical treatment of mild to moderate acne and designed to complement other acne treatments.</li>     <li>While a new drug application for Microcyn acne formulation has not yet been filed in the U.S., OCLS says a number of U.S. dermatologists have been using the Microcyn-based atopic dermatitis hydrogel since its  introduction in 2012.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1546801\" data-linked=\"Oculus Innovative Sciences +2.5% on European CE Mark for Microcyn\" data-tweet=\"$SNOA - Oculus Innovative Sciences +2.5% on European CE Mark for Microcyn https://seekingalpha.com/news/1546801-oculus-innovative-sciences-plus-2_5-percent-on-european-ce-mark-for-microcyn?source=tweet\" data-url=\"https://seekingalpha.com/news/1546801-oculus-innovative-sciences-plus-2_5-percent-on-european-ce-mark-for-microcyn\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:52 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1546791\" data-ts=\"1391529056\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FOSL\" target=\"_blank\">FOSL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1546791-fossil-rides-michael-kors-back-higher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fossil rides Michael Kors&#39; back higher</a></h4><ul> <li>Shares of Fossil (<a href='https://seekingalpha.com/symbol/FOSL' title='Fossil, Inc.'>FOSL</a> <font color='green'>+6%</font>) trade higher after Michael Kors <a href=\"https://seekingalpha.com/news/1546191-stunning-quarter-for-michael-kors-shares-plus-21-percent-early\" target=\"_blank\">reports</a> strong demand for watches and accessories.</li> <li>Analyst take:&nbsp;The big runup in Michael Kors has Jefferies tipping Fossil as the better value play.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"1546791\" data-linked=\"Fossil rides Michael Kors&#39; back higher\" data-tweet=\"$FOSL - Fossil rides Michael Kors&#39; back higher https://seekingalpha.com/news/1546791-fossil-rides-michael-kors-back-higher?source=tweet\" data-url=\"https://seekingalpha.com/news/1546791-fossil-rides-michael-kors-back-higher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:50 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1546771\" data-ts=\"1391528801\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UBS\" target=\"_blank\">UBS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1546771-shrinking-pays-off-for-ubs-but-valuation-is-pricey\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shrinking pays off for UBS; but valuation is pricey</a></h4><ul>\n<li>The bank has <a href=\"http://online.wsj.com/news/articles/SB10001424052702304851104579362510391876446?mod=rss_Heard_on_the_Street\" target=\"_blank\">spent the past couple of years</a> cutting back on capital-intensive businesses in the investment bank to focus on wealth management, and that unit contributed nearly half of operating profit in Q4 thanks to strong inflows, particularly out of Asia.</li>\n<li>The balance sheet is looking good too - with a core tier one equity ratio of 12.8%, just 20 basis points shy of the bank's target. The leverage ratio of 4.7% puts <a href=\"https://seekingalpha.com/symbol/UBS\" title=\"UBS Group AG\">UBS</a> ahead of rivals like Deutsche Bank and Barclays.</li>\n<li>The question is whether this is now priced in. UBS trades at about 1.6x estimated TBV for the end of 2014, well above the European average even as it delivered just a 8% ROE last year. Target ROE is 15% by 2015, though the bank says this may not be reached until 2016.</li>\n<li>\n<a href=\"https://seekingalpha.com/news/1545381\" target=\"_blank\">Earnings coverage</a> earlier</li>\n<li>The stock's <font color=\"green\">ahead 6%</font> thus far today.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1546771\" data-linked=\"Shrinking pays off for UBS; but valuation is pricey\" data-tweet=\"$UBS - Shrinking pays off for UBS; but valuation is pricey https://seekingalpha.com/news/1546771-shrinking-pays-off-for-ubs-but-valuation-is-pricey?source=tweet\" data-url=\"https://seekingalpha.com/news/1546771-shrinking-pays-off-for-ubs-but-valuation-is-pricey\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:46 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1546761\" data-ts=\"1391528279\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRM\" target=\"_blank\">CRM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1546761-salesforce-jumps-on-roth-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Salesforce jumps on Roth upgrade</a></h4><ul><li>Salesforce (<a href='https://seekingalpha.com/symbol/CRM' title='Salesforce.com, Inc.'>CRM</a> <font color='green'>+3.5%</font>) is closing in on its all-time high of $61.49 following an upgrade to Buy from Roth. Roth, whose ratings change is tied to a transfer of analyst coverage, has upped its Salesforce PT to $80.</li><li>Salesforce has <a href=\"https://www.google.com/finance?chdnp=1&amp;chdd=1&amp;chds=1&amp;chdv=1&amp;chvs=maximized&amp;chdeh=0&amp;chfdeh=0&amp;chdet=1391542200000&amp;chddm=7952&amp;chls=IntervalBasedLine&amp;cmpto=INDEXNASDAQ:.IXIC&amp;cmptdms=0&amp;q=NYSE:CRM&amp;ntsp=1&amp;ei=9QfxUrjDG8iciQLvDg\" target=\"_blank\">held up well</a> in the face of the recent market selloff. The company's FQ4 results are expected later this month.</li></ul><div class=\"tiny-share-widget\" data-id=\"1546761\" data-linked=\"Salesforce jumps on Roth upgrade\" data-tweet=\"$CRM - Salesforce jumps on Roth upgrade https://seekingalpha.com/news/1546761-salesforce-jumps-on-roth-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/1546761-salesforce-jumps-on-roth-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1546741\" data-ts=\"1391527695\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PFE\" target=\"_blank\">PFE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1546741-pfizer-plus-2_7-percent-on-jefferies-upgrade-based-on-reorg-potential-cancer-drug\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pfizer +2.7% on Jefferies upgrade based on reorg, potential cancer drug</a></h4><ul>     <li>Pfizer (<a href=\"https://seekingalpha.com/symbol/PFE\" title=\"Pfizer Inc.\">PFE</a> <font color=\"green\">+2.7%</font>) leads the Dow out of the gate after Jefferies <a href=\"http://www.streetinsider.com/Analyst+Comments/Jefferies+Upgrades+Pfizer+%28PFE%29+to+Buy%2C+%2438+PT/9120444.html\" target=\"_blank\">upgrades shares to Buy </a>from Hold and raises its target price to $38 from $33.</li>\n<li>The upgrade comes a day after PFE announced <a href=\"https://seekingalpha.com/news/1542971-pfizer-breast-cancer-drug-meets-main-phase-ii-goal\" target=\"_blank\">positive results</a> from its palbociclib experimental breast cancer treatment, which the firm believes could be approved as soon as the end of this year.</li>\n<li>The firm also likes PFE's reorganization of its commercial operations, which might make its business more  efficient and improve its tax structure; the creation of the division focused on  products that are losing protection also may prompt future acquisitions  or joint ventures.</li>      </ul><div class=\"tiny-share-widget\" data-id=\"1546741\" data-linked=\"Pfizer +2.7% on Jefferies upgrade based on reorg, potential cancer drug\" data-tweet=\"$PFE - Pfizer +2.7% on Jefferies upgrade based on reorg, potential cancer drug https://seekingalpha.com/news/1546741-pfizer-plus-2_7-percent-on-jefferies-upgrade-based-on-reorg-potential-cancer-drug?source=tweet\" data-url=\"https://seekingalpha.com/news/1546741-pfizer-plus-2_7-percent-on-jefferies-upgrade-based-on-reorg-potential-cancer-drug\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1546721\" data-ts=\"1391527537\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CPRI\" target=\"_blank\">CPRI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1546721-heard-during-michael-kors-earnings-call\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Heard during Michael Kors&#39; earnings call</a></h4><ul> <li>Execs with Michael Kors (KORS <font color=\"green\">+19.2%</font>) had a fairly easy time with the Q&amp;A during the firm's earnings call after the firm blasted past analyst estimates with its quarterly report.</li> <li>The game plan for the rest of the year remains the same: Grow comparable-store sales, expand the store base, and capitalize on e-commerce opportunities.</li> <li>Despite lower traffic in malls, conversion rates at Michael Kors stores were very high.</li> <li>Markdowns during the period were tied to late deliveries more than pressure from the overall retail sector. The company didn't see the need to go promotional which kept margins intact.</li> <li>Watch the footwear category, says management. Momentum is very strong and the upside potential enormous.</li> <li><a href=\"http://edge.media-server.com/m/p/knqfim42/lan/en\" target=\"_blank\">Earnings call transcript</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"1546721\" data-linked=\"Heard during Michael Kors&#39; earnings call\" data-tweet=\"$CPRI - Heard during Michael Kors&#39; earnings call https://seekingalpha.com/news/1546721-heard-during-michael-kors-earnings-call?source=tweet\" data-url=\"https://seekingalpha.com/news/1546721-heard-during-michael-kors-earnings-call\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:25 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1546701\" data-ts=\"1391526815\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZNGA\" target=\"_blank\">ZNGA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1546701-new-52-week-highs-for-zynga-following-ubs-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New 52-week highs for Zynga following UBS upgrade</a></h4><ul>\n<li>A day after Zynga (<a href=\"https://seekingalpha.com/symbol/ZNGA\" title=\"Zynga\">ZNGA</a> <font color=\"green\">+7.2%</font>) largely moved sideways in spite of a huge equity selloff and a downgrade to Underperform from BofA/Merrill, shares are shooting higher in response to an upgrade to Buy from UBS' <a href=\"http://www.streetinsider.com/Upgrades/UBS+Upgrades+Zynga+%28ZNGA%29+to+Buy+on+Renewed+Growth/9120439.html\" target=\"_blank\">Eric J. Sheridan</a>.</li>\n<li>Following the company's <a href=\"https://seekingalpha.com/news/1538671-zynga-releases-q4-report-early-buying-game-developer-for-527m\" target=\"_blank\">Q4 numbers</a>, Sheridan has \"increased confidence\" Zynga's core operations are stabilizing under new CEO Don Mattrick, and thinks its latest job cuts will lead EBITDA margins to bottom. 20%+ EBITDA margins are considered possible by 2015.</li>\n<li>He also thinks the NaturalMotion acquisition \"will result in a greater level of scale and innovation to the broader Zynga mobile game pipeline.\" Many tech writers have <a href=\"http://techcrunch.com/2014/01/30/zynga-naturalmotion/\" target=\"_blank\">made similar arguments</a>. Whereas Zynga is known for a data-driven approach to game development that focuses on rapid monetization, NaturalMotion CEO Torsten Reil brings a very different mindset to the table.</li>\n<li>Reil: \"We don\u2019t want to design [a title] to be a hard-core monetizing game. It has to be a delightful, wholesome experience.\"</li>\n<li>Sheridan thinks Zynga's Q1/2014 guidance will prove conservative, and sees room for NaturalMotion to grow by launching new titles, bringing existing ones to Android, and licensing its <a href=\"http://www.naturalmotion.com/middleware/euphoria/\" target=\"_blank\">Euphoria</a> animation engine.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1546701\" data-linked=\"New 52-week highs for Zynga following UBS upgrade\" data-tweet=\"$ZNGA - New 52-week highs for Zynga following UBS upgrade https://seekingalpha.com/news/1546701-new-52-week-highs-for-zynga-following-ubs-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/1546701-new-52-week-highs-for-zynga-following-ubs-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1546621\" data-ts=\"1391525282\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TPR\" target=\"_blank\">TPR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1546621-coach-beaten-back-by-michael-kors-blowout-quarter\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Coach beaten back by Michael Kors blowout quarter</a></h4><ul> <li>Shares of Coach (COH <font color='red'>-0.8%</font>) trade lower after rival Michael Kors rips a 28% comparable-store sales gain for its <a href=\"https://seekingalpha.com/news/1546191-stunning-quarter-for-michael-kors-shares-plus-21-percent-early\" target=\"_blank\">FQ3</a>.</li> <li>It's hard to argue that Coach didn't <a href=\"https://twitter.com/BrianSozzi/status/430682597950488576\" target=\"_blank\">lose</a> more market share to Michael Kors during the period, note retail analysts.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"1546621\" data-linked=\"Coach beaten back by Michael Kors blowout quarter\" data-tweet=\"$TPR - Coach beaten back by Michael Kors blowout quarter https://seekingalpha.com/news/1546621-coach-beaten-back-by-michael-kors-blowout-quarter?source=tweet\" data-url=\"https://seekingalpha.com/news/1546621-coach-beaten-back-by-michael-kors-blowout-quarter\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:48 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1546611\" data-ts=\"1391525165\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGNC\" target=\"_blank\">AGNC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1546611-american-capital-reverses-premarket-decline\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">American Capital reverses premarket decline</a></h4><ul>\n<li>After spending most of last night's after-hours sessions and this morning's premarket in the red, American Capital Agency (<a href=\"https://seekingalpha.com/symbol/AGNC\" title=\"AGNC Investment Corp.\">AGNC</a> <font color=\"green\">+1.1%</font>) moves higher in early regular session action.</li>\n<li>Yes, the <a href=\"https://seekingalpha.com/news/1544561-another-slide-in-book-value-at-american-capital-early-q1-looking-good\" target=\"_blank\">headline drop in book value</a> doesn't look good, but the decline suggests CIO Kain positioned the portfolio aggressively, meaning a big benefit thus far in 2014. It's possible Q4's drop in book has been reversed and more in the opening weeks of Q1. Net interest margins also widened a bit during Q4.</li>\n<li>Look for more color on the <a href=\"http://www.agnc.com/\" target=\"_blank\">earnings call</a> at 11 ET.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1546611\" data-linked=\"American Capital reverses premarket decline\" data-tweet=\"$AGNC - American Capital reverses premarket decline https://seekingalpha.com/news/1546611-american-capital-reverses-premarket-decline?source=tweet\" data-url=\"https://seekingalpha.com/news/1546611-american-capital-reverses-premarket-decline\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:46 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1546511\" data-ts=\"1391523340\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IPHYF\" target=\"_blank\">IPHYF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1546511-innate-added-to-goldman-conviction-list-shares-soar\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Innate added to Goldman conviction list, shares soar</a></h4><ul>     <li>Goldman Sachs has initiated coverage on Innate Pharma (<a href=\"https://seekingalpha.com/symbol/IPHYF\" title=\"Innate Pharma\">OTCPK:IPHYF</a>) and <a href=\"http://bourse.lefigaro.fr/indices-actions/actu-conseils/innate-pharma-prend-40-grace-a-des-propos-favorables-972297\" target=\"_blank\">added the company</a> to its buy conviction list, sending its shares up 41% to \u20ac10.8 in Paris.</li>    <li>Goldman also gave Innate a price target of \u20ac18,</li>    <li>Innate specializes in the development of immunotherapy drugs for the treatment of cancer and inflammatory diseases.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1546511\" data-linked=\"Innate added to Goldman conviction list, shares soar\" data-tweet=\"$IPHYF - Innate added to Goldman conviction list, shares soar https://seekingalpha.com/news/1546511-innate-added-to-goldman-conviction-list-shares-soar?source=tweet\" data-url=\"https://seekingalpha.com/news/1546511-innate-added-to-goldman-conviction-list-shares-soar\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1546481\" data-ts=\"1391523108\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1546481-premarket-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers / Losers</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/FURX' title='Furiex Pharmaceuticals, Inc.'>FURX</a> <font color='green'>+124%</font>. <a href='https://seekingalpha.com/symbol/ATMI' title='ATMI Inc.'>ATMI</a> <font color='green'>+25%</font>. <a href='https://seekingalpha.com/symbol/NLST' title='Netlist, Inc.'>OTC:NLST</a> <font color='green'>+25%</font>. KORS <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/ENTG' title='Entegris, Inc.'>ENTG</a> <font color='green'>+18%</font>. RSOL <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/RMTI' title='Rockwell Medical, Inc.'>RMTI</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/ZNGA' title='Zynga'>ZNGA</a> <font color='green'>+7%</font>. FULL <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/ITUB' title='Itau Unibanco Holding S.A.'>ITUB</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/UBS' title='UBS Group AG'>UBS</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/YUM' title='Yum! Brands, Inc.'>YUM</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ABIO' title='ARCA biopharma, Inc.'>ABIO</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/ARMH' title='ARM Holdings, plc'>ARMH</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/TTWO' title='Take-Two Interactive Software, Inc.'>TTWO</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"1546481\" data-linked=\"Premarket Gainers / Losers\" data-tweet=\"$FURX $ATMI $NLST - Premarket Gainers / Losers https://seekingalpha.com/news/1546481-premarket-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/1546481-premarket-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1546421\" data-ts=\"1391522336\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARCH\" target=\"_blank\">ARCH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1546421-arch-coal-minus-3_7-percent-after-bigger-than-expected-q4-loss-on-weak-sales\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arch Coal -3.7% after bigger than expected Q4 loss on weak sales</a></h4><ul>     <li>Arch Coal (NYSE:<a href=\"https://seekingalpha.com/symbol/ACI\" title=\"Albertsons Companies Inc\">ACI</a>) <font color=\"red\">-3.7%</font> premarket after reporting a bigger than expected <a href=\"https://seekingalpha.com/news/1546061-arch-coal-inc-misses-by-0_07-misses-on-revenue\" target=\"_blank\">Q4 loss</a> due to lower shipments and weak prices of both thermal and metallurgical coal; it was ACI's eighth consecutive quarterly loss.</li>     <li>ACI says rail service disruptions in Q4 hurt shipments of thermal coal, used to generate electricity, from its Powder River Basin mines in Wyoming, but did not specify the cause of the disruptions.</li>     <li>ACI earned $1.81/ton in consolidated cash margin at its Leer Mine vs. $3.03/ton in Q3, as its consolidated sales price rose 2%/ton while the consolidated cash cost price rose 10%/ton; similar decreases occurred at its Powder River Basin and in Appalachia operations.</li>     <li>Expects to sell 131.5M-142.5M tons of coal in 2014 vs. 139.6M tons in 2013.</li>\n<li>While thermal markets are gaining momentum, global met coal markets remain weak, ACI says; however, seaborne metallurgical prices are likely at unsustainably low levels, making it difficult to justify ongoing and  new capital investment.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1546421\" data-linked=\"Arch Coal -3.7% after bigger than expected Q4 loss on weak sales\" data-tweet=\"$ARCH - Arch Coal -3.7% after bigger than expected Q4 loss on weak sales https://seekingalpha.com/news/1546421-arch-coal-minus-3_7-percent-after-bigger-than-expected-q4-loss-on-weak-sales?source=tweet\" data-url=\"https://seekingalpha.com/news/1546421-arch-coal-minus-3_7-percent-after-bigger-than-expected-q4-loss-on-weak-sales\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1546281\" data-ts=\"1391520585\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JCP\" target=\"_blank\">JCP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1546281-j-c-penney-reports-first-positive-comp-since-2011\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">J.C. Penney reports first positive comp since 2011</a></h4><ul>     <li>J.C. Penney (NYSE:<a href=\"https://seekingalpha.com/symbol/JCP\" title=\"J.C. Penney Company Inc.\">JCP</a>) <a href=\"http://ir.jcpenney.com/phoenix.zhtml?c=70528&amp;p=irol-newsCompanyArticle&amp;ID=1896559&amp;highlight=\" target=\"_blank\">reports</a> a 2% increase in same-store sales during FQ4.</li>     <li>It's the first time the retailer pulled off a positive comp for a quarter since Q2 of 2011.</li>     <li>On liquidity, J.C. Penney says it ended the fiscal year north of the $2B mark.</li>     <li>JCP <font color=\"green\">+4.1%</font> premarket</li> </ul><div class=\"tiny-share-widget\" data-id=\"1546281\" data-linked=\"J.C. Penney reports first positive comp since 2011\" data-tweet=\"$JCP - J.C. Penney reports first positive comp since 2011 https://seekingalpha.com/news/1546281-j-c-penney-reports-first-positive-comp-since-2011?source=tweet\" data-url=\"https://seekingalpha.com/news/1546281-j-c-penney-reports-first-positive-comp-since-2011\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1546231\" data-ts=\"1391520127\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CPRI\" target=\"_blank\">CPRI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1546231-no-storm-clouds-for-michael-kors\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">No storm clouds for Michael Kors</a></h4><ul> <li>Michael Kors (KORS) blew past revenue estimates without sacrificing margins in FQ3. Gross profit as a percentage of total revenue was up 100 bps to 61.2% during the period.</li>\n<li>Weather and macroeconomic factors took a backseat to a brand that is on fire with consumers during the period.</li>\n<li>Expenses and inventory rose slower than sales in FQ3 for the retailer.</li> <li>Guidance for FQ4 is for revenue of $790M-$800M on the company's view that comparable store sales will increase by 15%-20%.</li> <li>SA contributor Stock Gamer had a well-reasoned <a href=\"https://seekingalpha.com/article/1961321-michael-kors-the-uptrend-will-continue\" target=\"_blank\">buy recommendation</a> on KORS into the earnings release and beyond.</li> <li>KORS <font color=\"green\">+19.8%</font> premarket to $91.75.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1546231\" data-linked=\"No storm clouds for Michael Kors\" data-tweet=\"$CPRI - No storm clouds for Michael Kors https://seekingalpha.com/news/1546231-no-storm-clouds-for-michael-kors?source=tweet\" data-url=\"https://seekingalpha.com/news/1546231-no-storm-clouds-for-michael-kors\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:22 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1546191\" data-ts=\"1391519186\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CPRI\" target=\"_blank\">CPRI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1546191-stunning-quarter-for-michael-kors-shares-plus-21-percent-early\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stunning quarter for Michael Kors, shares +21% early</a></h4><ul> <li>Michael Kors (KORS) soars in early trading after a smashing FQ3 earnings report.</li> <li>Comparable-store sales rose 28% during a period in which most retail peers were struggling to stay in positive territory.</li> <li>Wholesale sales rose 68.2% Y/Y to $461M and licensing revenue was up 59% to $47.4M.</li> <li>KORS <font color=\"green\">+21.1%</font> premarket</li> </ul><div class=\"tiny-share-widget\" data-id=\"1546191\" data-linked=\"Stunning quarter for Michael Kors, shares +21% early\" data-tweet=\"$CPRI - Stunning quarter for Michael Kors, shares +21% early https://seekingalpha.com/news/1546191-stunning-quarter-for-michael-kors-shares-plus-21-percent-early?source=tweet\" data-url=\"https://seekingalpha.com/news/1546191-stunning-quarter-for-michael-kors-shares-plus-21-percent-early\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1546121\" data-ts=\"1391518823\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PSEC\" target=\"_blank\">PSEC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1546121-buy-the-dip-in-prospect-says-wunderlich\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Buy the dip in Prospect says Wunderlich</a></h4><ul>\n<li>Valuation and the company's investments in multifamily real estate and consumer finance have analyst<a href=\"http://www.streetinsider.com/Analyst+Comments/Wunderlich+Raises+Prospect+Capital+%28PSEC%29+to+Buy+as+Dip+Creates+Opportunity/9120786.html\" target=\"_blank\"> Merill Ross boosting</a> Prospect Capital (NASDAQ:<a href=\"https://seekingalpha.com/symbol/PSEC\" title=\"Prospect Capital Corporation\">PSEC</a>) to a Buy with $12 price target the morning after the <a href=\"https://seekingalpha.com/news/1544751\" target=\"_blank\">company's Q4 results</a>.</li>\n<li>The stock has sold off along with the market, \"but as we look specifically at this company, we see an opportunity to generate a total return of over 24%, with 12% of that return in the form of monthly pay dividends.\"</li>\n<li>Shares <font color=\"green\">+2.7%</font> premarket</li>\n<li>The <a href=\"http://www.prospectstreet.com/\" target=\"_blank\">earnings call</a> is set for 11 ET</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1546121\" data-linked=\"Buy the dip in Prospect says Wunderlich\" data-tweet=\"$PSEC - Buy the dip in Prospect says Wunderlich https://seekingalpha.com/news/1546121-buy-the-dip-in-prospect-says-wunderlich?source=tweet\" data-url=\"https://seekingalpha.com/news/1546121-buy-the-dip-in-prospect-says-wunderlich\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1546021\" data-ts=\"1391517782\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FURX\" target=\"_blank\">FURX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1546021-furiex-eluxadoline-trial-results-smell-great-shares-soar\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Furiex Eluxadoline trial results smell great, shares soar</a></h4><ul>   <li>Furiex Pharmaceuticals' (NASDAQ:<a href=\"https://seekingalpha.com/symbol/FURX\" title=\"Furiex Pharmaceuticals, Inc.\">FURX</a>) Eluxadoline treatment for diarrhea-predominant irritable bowel syndrome (IBS-d) met the goals of two Phase III trials by improving stool consistency and relieving abdominal pain.</li>    <li>Furiex now plans to apply for FDA approval of Eluxadoline by the middle of the year and for EU authorization in early 2015.</li>    <li>IBS-d affects  28M people in the U.S. and major European markets. Furiex founder and chairman Fred Eshelman reckons the drug could bring in annual sales of $750M-$1B.</li>        <li>Eshelman has sparked <a href=\"http://www.fiercebiotech.com/story/furiex-preps-buyout-talks-after-ibs-drug-looks-promising-phiii/2014-02-04\" target=\"_blank\">buyout talk</a> by saying that the company would launch the drug itself \"if we don't get offers.\" However, the firm would have to raise money.</li>\n<li>Shares <font color=\"green\">+78%</font>. (PR)</li>     </ul><div class=\"tiny-share-widget\" data-id=\"1546021\" data-linked=\"Furiex Eluxadoline trial results smell great, shares soar\" data-tweet=\"$FURX - Furiex Eluxadoline trial results smell great, shares soar https://seekingalpha.com/news/1546021-furiex-eluxadoline-trial-results-smell-great-shares-soar?source=tweet\" data-url=\"https://seekingalpha.com/news/1546021-furiex-eluxadoline-trial-results-smell-great-shares-soar\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:43 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1545401\" data-ts=\"1391502896\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARMH\" target=\"_blank\">ARMH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1545401-arm-swings-to-q4-loss-of-6_2m-shares-sink\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ARM swings to Q4 loss of £6.2M, shares sink</a></h4><ul>   <li>ARM Holdings (NASDAQ:<a href=\"https://seekingalpha.com/symbol/ARMH\" title=\"ARM Holdings, plc\">ARMH</a>) <a href=\"http://online.wsj.com/news/articles/SB10001424052702304851104579362050092151552\" target=\"_blank\">swung to a net loss</a> off £6.2M in Q4 from a profit of £42.5M a year earlier, with the microchip designer hurt by  one-off charges such as payroll taxes and impairments.</li>    <li>Adjusted pretax profit rose 19% to £95.5M.</li>    <li>Revenue climbed 15% to £189.1M, topping estimates of £181.8M, although growth was limited by slower sales of chips for high-end smartphones.</li>    <li>Processor royalty revenue +7% in U.S.-dollar terms and licensing revenue +26%.</li>    <li>2.9B chips using ARM technology shipped, +16%.</li>    <li>Signed 26 processor licenses.</li>    <li>ARM has \"a strong opening order backlog and a healthy pipeline of licensing opportunities,\" and it expects full-year 2014 processor royalty revenues \"to grow at a similar rate to that reported over the last three years.\" The company also forecasts overall revenue to be in line with market expectations.</li>\n<li>Shares <font color=\"red\">-4.35%</font> in London. (PR)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1545401\" data-linked=\"ARM swings to Q4 loss of £6.2M, shares sink\" data-tweet=\"$ARMH - ARM swings to Q4 loss of £6.2M, shares sink https://seekingalpha.com/news/1545401-arm-swings-to-q4-loss-of-6_2m-shares-sink?source=tweet\" data-url=\"https://seekingalpha.com/news/1545401-arm-swings-to-q4-loss-of-6_2m-shares-sink\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:34 AM </div></div></li>","count":57,"message":null,"success":true,"today":{"start":1576904400,"end":1576990799,"str":"Saturday, December 21, 2019"},"yesterday":{"start":1576818000,"end":1576904399}}